Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
UTHR vs. CORT: Which Stock Should Value Investors Buy Now?
12:47pm, Friday, 11'th Nov 2022
UTHR vs. CORT: Which Stock Is the Better Value Option?
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
12:03pm, Friday, 04'th Nov 2022
Corcept's (CORT) third-quarter 2022 earnings beat estimates while revenues miss the same. The company tightens its revenue guidance for 2022.
Corcept Therapeutics Incorporated (CORT) Q3 2022 Earnings Call Transcript
11:11pm, Thursday, 03'rd Nov 2022
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Joseph Belanoff - CEO and President Atabak Mokari - CFO Bill Guyer -
Corcept Therapeutics (CORT) Tops Q3 Earnings Estimates
09:05pm, Thursday, 03'rd Nov 2022
Corcept (CORT) delivered earnings and revenue surprises of 30.43% and 5.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Thursday, 27'th Oct 2022
MENLO PARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on
Corcept (CORT) Thrives on Korlym, Overdependence a Concern
12:47pm, Thursday, 20'th Oct 2022
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
7 Under-the-Radar Stocks With 100% Upside Potential
06:45am, Monday, 17'th Oct 2022
The markets have delivered one of the worst years in the past several decades. As a result, investors are left searching for under-the-radar stocks that have been passed over due to all the bad news.
Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS
12:04pm, Wednesday, 12'th Oct 2022
Corcept (CORT) starts the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant for treating patients with amyotrophic lateral sclerosis.
Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why
03:44pm, Wednesday, 14'th Sep 2022
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
2 Top Biotech Stocks Defying the Bear Market
10:30am, Saturday, 10'th Sep 2022
Both could see record sales throughout the next few years.
2 Growth Stocks That Are Beating Amazon Without Breaking a Sweat
10:53am, Saturday, 03'rd Sep 2022
They're both cornering specialized markets and growing aggressively in the process.
ASRT or CORT: Which Is the Better Value Stock Right Now?
12:48pm, Thursday, 25'th Aug 2022
ASRT vs. CORT: Which Stock Is the Better Value Option?
JAZZ or CORT: Which Is the Better Value Stock Right Now?
12:47pm, Tuesday, 09'th Aug 2022
JAZZ vs. CORT: Which Stock Is the Better Value Option?
Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y
09:47am, Friday, 05'th Aug 2022
Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2022 Results - Earnings Call Transcript
10:23pm, Wednesday, 03'rd Aug 2022
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Joseph Belanoff - Chief Executive Officer, President, and Director Atab
